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Abstract
Chronic pancreatitis (CP) is a complex disease that should be 
treated by experienced teams of gastroenterologists, radi-
ologists, surgeons, and nutritionists in a multidisciplinary en-
vironment. Medical treatment includes lifestyle modifica-
tion, nutrition, exocrine and endocrine pancreatic insuffi-
ciency correction, and pain management. Up to 60% of 
patients will ultimately require some type of endoscopic or 
surgical intervention for treatment. However, regardless of 
the modality, they are often ineffective unless smoking and 
alcohol cessation is achieved. Surgery retains a major role in 
the treatment of CP patients with intractable chronic pain or 
suspected pancreatic mass. For other complications like bil-
iary or gastroduodenal obstruction, pseudocyst drainage 
can be performed endoscopically. The recommendations for 
CP were developed by Clube Português do Pâncreas (CPP), 
based on literature review to answer predefined topics, sub-
sequently discussed and approved by all members of CPP. 
Recommendations are separated in two parts: “chronic pan-
creatitis etiology, natural history, and diagnosis,” and “chron-
ic pancreatitis medical, endoscopic, and surgical treatment.” 
This abstract pertains to part II.
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Resumo
A pancreatite crónica (PC) é uma doença complexa que 
deve ser tratada por equipas multidisciplinares experien-
tes de gastrenterologistas, radiologistas, cirurgiões e nu-
tricionistas. O tratamento médico inclui modificação do 
estilo de vida, nutrição, correção das insuficiências pan-
creáticas endócrina e exócrina e controle da dor. Até 60% 
dos doentes podem necessitar de algum tipo de terapêu-
tica endoscópica ou cirúrgica. No entanto, independente-
mente da modalidade, elas serão ineficazes, se não se al-
cançar cessação tabágica e etílica. A cirurgia desempenha 
um papel importante no tratamento dos doentes com dor 
crónica intratável ou lesões pancreáticas suspeitas. Out-
ras complicações como obstrução biliar, gastroduodenal, 
ou drenagem de pseudocistos podem ser tratadas endo-
scopicamente. As recomendações sobre PC foram desen-
volvidas pelo Clube Português do Pâncreas (CPP), com 
base numa revisão da literatura para responder a questões 
predefinidas, posteriormente discutidos e aprovados por 
todos os membros do CPP. As recomendações encon-
tram-se separadas em duas partes: “etiologia da pancre-
atite crónica, história natural e diagnóstico” e “tratamento 
médico, endoscópico e cirúrgico da pancreatite crónica.” 
Este resumo corresponde à parte II.
© 2019 Sociedade Portuguesa de Gastrenterologia  
Publicado por S. Karger AG, Basel
Introduction
This paper refers to part II of Clube Português do Pân-
creas (CPP) recommendations for chronic pancreatitis 
(CP) management. The recommendations were initially 
based on literature review to answer predefined topics, 
subsequently discussed and approved by all members of 
CPP.
Statement 
CP requires several treatments (Fig. 1). Pain manage-
ment should be dealt with multidisciplinarily, with the 
several available therapeutic measures including nutri-
tion, lifestyle modifications, pancreatic enzyme replace-
ment therapy (PERT), and analgesics. CPP recommends 
alcohol and tobacco abstinence, a normal polyfraction-
ated diet, and PERT. Analgesia should start with para-
cetamol. If unresponsive, tramadol is recommended and/
or combination with pregabalin. Nortriptyline is a useful 
adjuvant and, if necessary, analgesia may escalate to 
strong opioids. Patients with pancreatic exocrine insuf-
ficiency (PEI) should start PERT and titrate the dose 
(with a proton pump inhibitor [PPI]) until symptom res-
olution and normalization of nutritional status. Serum 
levels of vitamins A, D, E, K, and B12 and secondarily cal-
cium, magnesium, zinc, thiamine, and folic acid need to 
be evaluated. All patients should undergo an annual fast-
ing glucose and HbA1c and be treated accordingly if en-
docrine insufficiency is diagnosed. Mild hyperglycemia 
in the initial phases of disease may be controlled with oral 
hypoglycemic agents; however, in advanced disease, in-
sulin is the only effective therapy.
Surgery retains a major role in the treatment of CP pa-
tients with intractable chronic pain or suspected pancre-
atic mass. Pancreatoduodenectomy (PDD) and distal 
pancreatic resections should be the treatment of choice in 
cases where malignancy is suspected. However, endo-
scopic therapy should be considered as a first-line therapy 
for painful uncomplicated CP, since it is less invasive and 
may reduce or delay the need for surgery. If clinical suc-
cess can be obtained with ≤5 endoscopic interventions, 
the patient will probably achieve a long-term favorable 
outcome. The best candidates for successful treatment of 
painful CP are patients with distal obstruction of the main 
pancreatic duct (MPD) (single stone and/or single stric-
ture in the head of the pancreas) and in the early stages of 
the disease. For other complications like biliary or gastro-
duodenal obstruction, pseudocyst drainage should also 
be performed endoscopically.
Medical Treatment
Lifestyle Modification
Abstinence from alcohol and tobacco are essential and 
mandatory components of medical guidance. Alcohol ab-
stinence has a significant effect on endocrine pancreatic 
function [1]. Although there is a maintained deteriora-
tion in pancreatic exocrine function, both in patients who 
stop alcohol and in those who continue, the process is 
significantly less marked in patients who stop drinking 
[2]. Alcohol intake, even less than 50 g/day, induces ear-
lier disease characterized by more frequent severe pain, 
pancreatic calcifications, and complications. Intake of 
large amounts of alcohol (≥50 g/day) accelerates calcifi-
cation and reduces life expectancy [3]. 
Tobacco smoking is an independent risk factor for 
pancreatitis and accelerates the course of CP in a dose-
dependent way, apart from alcohol intake [4–6]. Even for 
idiopathic CP, smoking has been extensively demonstrat-
ed as an independent risk factor [7]. Tobacco cessation 
appears to be associated with even more benefits as it also 
reduces the risk of secondary pancreatic carcinoma. The 
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International Pancreatic Cancer Case-Control Consor-
tium demonstrated an odds ratio (OR) for pancreatic 
cancer of 1.2 for former smokers and 2.2 for current 
smokers, with a significant increasing trend in risk with 
increasing number of cigarettes among current smokers 
(OR 3.4 for ≥35 cigarettes/day). Risk increased in relation 
to duration of cigarette smoking up to 40 years of smok-
ing (OR 2.4), and seems to decrease with time since ces-
sation, reaching the level of never-smokers approximate-
ly 20 years after quitting [8]. 
Nutrition
Malnutrition is common in CP, which is aggravated 
because up to 50% of patients have increased resting en-
ergy expenditure, and its severity is a major predictive 
factor of complications and outcome. Although reduced-
fat diet may permit partial symptom control, fat content 
should be normal (30% of total energy intake) to prevent 
malnutrition. In fact, the European Society for Clinical 
Nutrition and Metabolism advocates a normal diet sup-
plemented by pancreatic enzymes for the vast majority of 
patients [9]. Ten to 15% will require nutritional supple-
ments and only 5% tube feeding. Deficiencies in vitamins 
A, D, E, and K (secondary to steatorrhea), and in vitamin 
B12, calcium, magnesium, zinc, thiamine, and folic acid 
can also occur; so, they should be considered and supple-
mented if necessary [9, 10]. 
Exocrine Pancreatic Insufficiency
The role of PERT in patients with CP is inconclusive; 
a recent systematic review and meta-analysis of 17 ran-
domized controlled trials demonstrated a statistically sig-
nificant superiority of PERT versus placebo in terms of 
coefficient of fat absorption, coefficient of nitrogen ab-
sorption, reduced fecal fat and nitrogen excretion, fecal 
weight, and abdominal pain. The follow-up studies also 
demonstrated improvement of serum nutritional param-
eters, gastrointestinal symptoms, and quality of life. All 
these gains were achieved without significant adverse 
events [11]. Therefore, PERT is recommended in patients 
with significant steatorrhea (> 15 g/day) and symptom-
atic steatorrhea (diarrhea, weight loss, or other signs of 
malnutrition) [12]. The benefit in treating asymptomatic 
patients with less severe steatorrhea (from 7.5 to 15 g/day) 
is not clear [13].
Typically, steatorrhea develops when the pancreatic li-
pase production falls to < 10% of normal. With the objec-
tive of controlling this, a minimal dosing of 25,000–50,000 
IU of lipase per meal is required (providing approximate-
ly 10% of the physiologic pancreatic secretion). One cap-
Chronic pancreatitis diagnosis
Alcohol and tobacco abstinence
Pancreatic
endocrine/exocrine
insufficiency
ComplicationsPain
Endocrine/exocrine
replacement
therapy
Pancreatic pseudocyst Biliary or gastro-
duodenal obstruction
Pancreatic fistula
Endoscopic drainage
Surgical treatment
Surgical treatmentSurgical
treatmentSurgical treatment
Endoscopic/ESWL treatment
Medical conservative
treatment
Biliary stent placement
Gastrojejunal anastomosis
Endoscopic
treatment
Conservative medical treatment
Lifestyle guidance
Normal polyfractionated diet
Analgesics/antispasmodics/narcotics
Fig. 1. Algorithm approach to therapy of chronic pancreatitis.
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sule should be swallowed at the beginning of the meal 
(including small meals or snacks), and for major meals a 
second dosage should be administered during the meal to 
ensure an adequate release of enzymes throughout diges-
tion. Patients who do not respond adequately to PERT 
should initiate a PPI, which is obligatory from the initia-
tion of therapy in non-enteric-coated enzymes. Dose in-
crease, if necessary, should be slow and accompanied by 
careful monitoring and symptom checking. In general, 
dosage should not exceed 10,000 IU lipase/kg of body 
weight per day. Failure to improve steatorrhea after dose 
optimization and PPI should lead to investigate low pa-
tient compliance, intestinal bacterial overgrowth (present 
in one-third of patients) [14], intestinal infections, or oth-
er disorders associated with malabsorption [15].
There is a considerable variation in different countries 
in PERT dosage, enteric-coating, formulations (granules, 
tablets, microspheres, minimicrospheres, or capsules), 
kinetics of duodenal lipase release, and bioequivalence 
[16]. High-dose or enteric-coated enzymes showed a 
trend to greater effectiveness than low-dose or noncoated 
[11]. In Portugal, there are two formulations of enteric-
coated, gastroresistant capsules. These enteric-coated 
capsules of minimicrospheres contain amylase 8,000 U + 
lipase 10,000 U + protease 600 U, and amylase 18,000 U 
+ lipase 25,000 U + protease 1,000 U, respectively, under 
the trademark of Kreon® and Kreon® 25,000. There is 
one low-dose, nonenteric tablet formulation (amylase 
6,000 U + lipase 6,000 U + protease 400 U + dimeticone 
80 mg under the trademark of Pankreoflat®) but has not 
an approved indication for the treatment of PEI [17]. 
The main objective of PERT is to avoid symptoms as-
sociated with PEI (diarrhea, weight loss, bloating) and 
normalize nutritional status. This should be assessed by 
evaluating body weight and weight loss, considering sev-
eral factors such as nutrient intolerance, dietary intake 
and restrictions, symptoms of specific nutrient deficien-
cies, anthropometry, biochemical test, lymphocyte count, 
muscle function, and nutritional indexes. Alcohol or drug 
abuse should also be considered. The response to PERT 
can be objectively measured with 13C-mixed triglyceride 
breath test or the coefficient of fat absorption (CFA quan-
tification). After symptom control, the chosen test should 
be repeated with increasing PERT doses until it attains a 
normal value. This approach is associated with a normal-
ization of the body mass index and the nutritional status 
of patients. However, for most patients, symptoms and 
nutritional status are sufficient for monitoring response 
to treatment [13]. 
Endocrine Pancreatic Insufficiency
Depending on the cohort, diabetes mellitus (DM) has 
been described in 26–80% of CP patients. In this context, 
DM is categorized as pancreatogenic diabetes (type 3), 
which is characterized by an absent pancreatic polypep-
tide response to mixed-nutrient ingestion [18]. Risk fac-
tors for DM3 in CP include longstanding duration of dis-
ease, prior partial pancreatectomy, and early onset of cal-
cifications. Patients developing DM3 are likely to have 
PEI. The initial evaluation of CP patients includes fasting 
glucose and HbA1c. The PancreasFest recommendations 
for diabetes advocate annual repetition of these tests [18]. 
The main endocrine defect in these patients is insulin de-
ficiency but they also carry a greater risk of hypoglycemia 
when treated with insulin. In initial phases of disease, 
controlling mild hyperglycemia with oral hypoglycemic 
agents may be valid. In advanced disease, insulin is the 
only effective therapy, with dosing and regimen following 
the general recommendations for type 1 diabetes [18].
Pain Management
Pain is the most common symptom of CP and proba-
bly the most debilitating and challenging to treat. Most 
patients need some form of analgesia [19]. Significant 
worsening of pain or change of the usual characteristics 
or pattern usually implies a differential diagnosis to con-
firm that it is only an exacerbation of the disease and not 
another complication. After confirming pain due to CP, 
medical approach should begin with optimization of gen-
eral measures and PERT. Subsequently, analgesic therapy 
should be escalated. Analgesics should be consumed be-
fore the meal, since a reduction in postprandial pain re-
sults in an increased food intake [9].
Pregabalin, tramadol, and morphine showed a potent 
analgesic effect in severe CP pain [20, 21]. Tramadol 
should be preferred as it interferes less with gastrointesti-
nal function. Nonsteroidal anti-inflammatory drugs 
should preferentially not be used long-term due to their 
gastrointestinal adverse effects and because patients with 
alcoholic CP have a higher prevalence of peptic ulcers 
[22]. 
Pain processing by the central nervous system is ab-
normal in CP and resembles that observed in patients 
with neuropathic pain disorders. Therefore, strategies 
used for neuropathic pain should be transposed to CP. In 
this context, combined gabapentin and nortriptyline 
seems to be more efficacious than either drug given alone 
for neuropathic pain, and so, the use of this combination 
in patients who show a partial response to either drug 
given alone is recommended [23].
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When pain occurs, it should be promptly dealt with by 
administering an oral analgesic in the following order: 
nonopioids (paracetamol); then, if necessary, mild opi-
oids (tramadol) and finally, if unresponsive, strong opi-
oids such as morphine. Adjuvants (such as nortriptyline) 
are extremely useful for controlling anxiety and fear as-
sociated with pain and can be initiated from the first step. 
In patients with frequent pain episodes, there should be a 
regular administration of analgesics to maintain pain 
freedom instead of an “on demand” strategy [24]. 
Endoscopic Treatment
Between 30 and 60% of patients with CP will ultimate-
ly require some type of endoscopic or surgical interven-
tion for treatment. Endoscopic techniques are often used 
in combination with medical therapy and attempted be-
fore major operative interventions are pursued. However, 
regardless of the modality, they are often ineffective un-
less smoking and alcohol cessation is also achieved [25].
Intractable pain is the most common indication for 
endoscopic therapy, and treatment should be considered 
before patients become opiate-dependent. Endoscopic 
therapy should be considered as the first-line therapy for 
painful uncomplicated CP. Clinical response should be 
evaluated at 6–8 weeks; if unsatisfactory, patient’s case 
should be reevaluated and surgical options should be 
considered, in particular in those with a predicted poor 
outcome following endoscopic therapy [26].
Endoscopic retrograde cholangiopancreatography 
can achieve MPD drainage by sphincterotomy of the ma-
jor and/or minor papilla, short-term stent placement or 
pancreatic stone extraction, usually after fragmentation 
with extracorporeal shock wave lithotripsy (ESWL). The 
best candidates for successful treatment of painful CP are 
patients with distal obstruction of the MPD (single stone 
and/or single stricture in the head of the pancreas) and in 
the early stages of the disease [27].
Pancreatic Duct Stones
Pancreatic duct (PD) stones are a common complica-
tion of CP and produce pain by causing upstream dilation 
and ductal hypertension. They are seen in approximately 
50% of patients with CP. Stones smaller than 5 mm with-
out any evidence of MPD stricture can typically be re-
moved by a Dormia basket or an extraction balloon after 
pancreatic sphincterotomy. Complete or partial pain re-
lief after pancreatic sphincterotomy and mechanical 
stone extraction is seen in 50–77%. These methods have 
some limitations in cases of stones greater than 5 mm in 
diameter, located upstream of an MPD stricture or im-
pacted in the head of the pancreas, in which case adjunc-
tive therapies or devices to fragment the stones may be 
needed [28, 29]. The European Society of Gastrointestinal 
Endoscopy (ESGE) recommends ESWL as a first step, fol-
lowed sometimes by endoscopic extraction of stone frag-
ments in the presence of large (> 5 mm) obstructive 
stone(s) located in the pancreatic head, and with ductal 
stenting in the presence of a dominant MPD stricture that 
induces a markedly dilated duct [26, 27]. ESWL should be 
considered for patients with recurrent attacks of pancre-
atic pain, moderate to marked changes in the pancreatic 
ductal system and obstructing ductal stones. Factors as-
sociated with long-term pain relief are short disease dura-
tion, low frequency of pain attacks before treatment, 
complete ductal stone clearance, absence of MPD stric-
ture, and discontinuation of alcohol and tobacco [27].
Early studies have shown that stone removal from the 
MPD leads to symptomatic improvement in a consider-
able proportion of CP patients [28, 30]. However, the 
quality of evidence of reported results remains low in 
most of these retrospective observational nonrandom-
ized studies. Only two randomized controlled trials com-
pared endoscopic therapy and surgery, and both favored 
surgery. There were, however, several shortcomings, like 
low technical success rate and suboptimal procedures 
compared with previous studies. Endoscopic therapy 
should be an option since it is less invasive, being possible 
in patients with risk factors such as older age and comor-
bidities, and may reduce or delay the need for surgery. If 
clinical success can be obtained with ≤5 endoscopic in-
terventions, the patient will probably achieve long-term 
favorable outcome [27].
PD Strictures
MPD strictures are identified in many patients with 
CP [31]. Although in most cases they are benign, malig-
nancy should be carefully excluded. Similar to PD stones, 
the aim of therapy is to decompress the ductal system by 
alleviating the narrowed segments.
The most commonly used approach involves pancre-
atic sphincterotomy, followed by dilation of the stricture, 
and placement of a PD stent [32]. The stent size should 
be at least as large as the MPD, in order to dilate the ste-
nosis. A 10-Fr stent is less likely to be obstructed, although 
its placement is more difficult than a 5-Fr stent. The stents 
should be long enough to overpass the stenosis, and short 
enough to minimize ductal changes. 
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A prospective study reported rapid symptomatic im-
provement following insertion of a pancreatic stent in 
nonoperable patients, although further interventions 
were frequently needed [33]. Removal of the obstruction 
of the MPD is effective for the treatment of pain in the 
short term, with reported success rates ranging from 37 
to 94%. A large study reported long-term pain relief in 
84% of patients [31]. The same study showed that 79 and 
97% of patients required new stent therapy for pain con-
trol within 1 and 2 years after the first procedure, respec-
tively.
There is no consensus for how long stent therapy 
should be pursued, though some studies suggested that 
placement of a stent every 6 months achieves symptom-
atic control in the majority of patients. It should be noted 
that MPD stenting is associated with complications such 
as stent occlusion and stent migration. The ESGE recom-
mends treating dominant MPD strictures by inserting a 
single 10-Fr plastic stent, with stent exchange planned 
within 1 year even in asymptomatic patients to prevent 
complications related to longstanding pancreatic stent 
occlusion [26]. Simultaneous placement of multiple, side-
by-side, pancreatic stents could be applied more exten-
sively, particularly in patients with MPD strictures per-
sisting after 12 months of single plastic stenting. Even 
though preliminary studies suggest temporary placement 
of fully covered self-expandable metal stents (FCSEMS) 
is safe and allows resolution of MPD strictures plus pain 
relief in a majority of patients, it should only be per-
formed in the setting of trials [26].
Pancreatic Pseudocysts
Pseudocysts develop in 20–40% of patients with CP. 
Intraductal hypertension within the MPD or the rupture 
of a branching duct can lead to its formation. Drainage is 
indicated in pseudocysts that do not resolve spontane-
ously and are symptomatic, in particular if pain, infec-
tion, or evidence of obstruction occurs [34–36]. Pseudo-
cyst drainage can be done percutaneously, endoscopical-
ly, or surgically. Compared with surgery, endoscopic 
drainage provides similar long-term results at a lower 
cost, shorter hospital stay, better quality of life during the 
first months following treatment, and a slightly lower 
procedure-related mortality.
When drainage is indicated, and before selecting the 
endoscopic approach, it is essential to accurately deter-
mine whether there is communication with the main or 
secondary PDs [37]. There are two different endoscopic 
strategies for managing pseudocysts. Transpapillary 
drainage involves directly inserting a stent through the 
MPD into the collection, or trying to bridge the defect 
with a stent to prevent further leakage and redirect the 
flow of pancreatic juices back into the bowel. Transmu-
ral drainage consists of placement of double pigtail or 
self-expandable lumen-apposing metal stents (LAMS) 
from the stomach or the duodenum into the cyst cavity. 
Cystoduodenostomy should be preferred over cystogas-
trostomy if both routes are deemed equally feasible [37]. 
At least two double-pigtail plastic stents should be 
placed and should not be retrieved before cyst resolu-
tion as determined by cross-sectional imaging [26]. 
Whether drainage by plastic or LAMS leads to a better 
outcome or to fewer complications is still being debated 
[37]. Depending on the location, combined trans-
sphincter, transmural, or transabdominal ultrasound 
and CT-guided or laparoscopic procedures may be nec-
essary. Both approaches offer high rates of clinical suc-
cess [38]. However, it should be pointed out that the 
technical success of transpapillary drainage is lower 
compared to the transmural approach. It should be re-
served for small (< 5 cm) communicating pseudocysts 
associated with a partial MPD disruption [39]. Since 
this approach may be associated with lower rates of 
bleeding and perforation, at the same time it allows for 
detection of MPD strictures and stones. However, the 
transpapillary approach may be burdened by the risks 
of acute pancreatitis, MPD scarring, or superinfection 
of the pseudocyst.
Celiac Plexus Block
The aim of celiac plexus block is to disrupt the trans-
mission of afferent pain signals from the pancreas. It typ-
ically involves the injection of the celiac plexus with a lo-
cal anesthetic mixed with a corticosteroid. EUS-guided 
approach is preferred over CT-guided approach since the 
former is associated with fewer side effects [40]. A pro-
spective randomized study, comparing EUS versus CT-
guided celiac plexus block, reported pain relief in some 
50% of patients in the EUS group, a percentage that was 
higher than that achieved when the procedure was per-
formed under CT guidance [40, 41].
Several studies report the success rate as high as 95%. 
However, and despite high rates of technical success, the 
efficacy in terms of long-term pain relief is disappointing. 
While short-term pain improvement is achieved in near-
ly half of patients, pain improvement 24 weeks after the 
procedure was reported in only 10% of patients. Given the 
low long-term success rates, EUS-guided celiac plexus 
block should be considered as a temporary measure. 
ESGE recommends considering celiac plexus block only 
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as a second-line therapy in patients with limited options 
and reinforces that a EUS-guided approach should be 
preferred over a percutaneous one [26]. 
Benign Biliary Strictures
Benign biliary strictures are frequent in patients with 
CP, with an estimated prevalence of 3–46% [42]. Patients 
with biliary strictures may present with cholestasis, symp-
toms (pain, nausea, weight loss, jaundice, and pruritus), 
cholangitis, and biliary cirrhosis. Besides the presence of 
symptoms, indications for endoscopic intervention in-
clude the development of secondary biliary cirrhosis, 
common bile duct stones, worsening of the stricture 
based on increased proximal biliary ductal dilation, and 
persistent (> 1 month) jaundice or alkaline phosphatase 
elevation (2–3 times the upper limit of normal) [26].
Endoscopic management usually involves biliary 
stenting by endoscopic retrograde cholangiopancreatog-
raphy. Balloon dilation alone is rarely performed, since 
strictures in this setting do not resolve easily. Placement 
of temporary (1-year) multiple, side-by-side, plastic bili-
ary stents is recommended; an alternative approach is the 
placement of SEMS. Like stents in the MPD, stents in the 
bile duct need to be regularly exchanged to prevent occlu-
sion and cholangitis. A suggested exchange interval for 
plastic stents is 3 months, whereas FCSEMS remain pat-
ent for 6 months or longer [37]. The rate of stricture res-
olution with plastic biliary stent placement is around 37% 
over 32 months, while SEMS patency is reported to range 
from 37 to 100% over a mean follow-up of 45 months 
[43]. A systematic review comparing the two approaches 
showed that clinical success was greater with SEMS (80%) 
compared with single plastic stents (36%) [44]. However, 
other studies have shown very high success rates with 
multiple plastic stents [45], and therefore, current guide-
lines favor this as the initial approach and do not yet sup-
port routine use of biliary SEMS for this indication [26]. 
However, FCSEMS seem to improve outcomes in case se-
ries and nonrandomized and randomized trials, with a 
stricture resolution rate of 76–93% and a recurrence rate 
of strictures of only 14–15% [37].
Surgical Treatment
For the most part of the 20th century, pancreatic resec-
tion surgery was associated with prohibitive morbidity 
and mortality, leading some authors to condemn this 
procedure as recently as in the 1970s [46]. At the begin-
ning of the 1990s, with the advent of specialized centers 
in pancreatic surgery, there was a huge improvement in 
surgical outcomes [47, 48]. 
The history of CP surgery did not follow the same path 
as pancreatic resection surgery. Since resection results 
were so discouraging, surgeons pursued a different path 
in CP surgery, often preferring drainage to resection. Al-
though surgery should be considered the best long-term 
option for pain management in CP, there is still no con-
sensus about the best procedure. Drainage procedures 
like Partington and Rochelle pancreatojejunostomy [49] 
are a very safe option in patients with substantially dilated 
PD (> 7 mm), but this only occurs in less than a quarter of 
patients [50]. Furthermore, this approach has proven in-
sufficient to deal with pain when the pancreatic head is 
not adequately drained [51].
When CP is associated with inflammatory mass of the 
head of the pancreas, pancreatic head resection, associ-
ated or not to a drainage procedure, is the technique of 
choice [52]. The supporters of duodenal preserving pan-
creatic head resection (DPPHR) argue that this procedure 
improves endocrine and exocrine functions and results in 
better postoperative quality of life, when compared to 
PDD [53, 54]. It is not easy to say which DPPHR proce-
dure is the best. The Berne technique is easier to perform 
than the Beger procedure, but there are no significant dif-
ferences between them in relevant patient outcomes [55].
There is a consensus that PDD and distal pancreatic 
resections should be the treatment of choice in cases 
when malignancy is suspected [52]. Once CP features are 
present, the ability to differentiate between inflammation 
and pancreatic cancer is limited with current imaging or 
endoscopic ultrasound. When a suspicious pancreatic 
mass is present, even in the absence of pathologic confir-
mation, resection should be performed [52]. A prospec-
tive trial comparing PDD with DPPHR concluded that 
patients submitted to DPPHR have better quality of life 
scores [56]. Although both procedures significantly im-
prove quality of life, the improvement may be more sig-
nificant in DPPHR [57]. However, long-term results may 
not be significantly different in terms of quality of life, 
pain control, or other somatic parameters [58]. Because 
CP surgical caseload is small, a good argument in favor of 
PDD is that it is a much more frequently performed op-
eration and it is what a hepato-pancreato-biliary surgeon 
is more comfortable with.
The goals of total pancreatectomy with islet cell auto-
transplant (TP-IAT) are to treat continuous pain, in-
crease quality of life, and prevent pancreatic cancer [59]. 
Especially in North America, enthusiasts suggest that it 
has a definite role in the treatment of CP, particularly in 
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patients that present with parenchymal calcifications in-
volving the whole organ with nondilated MPD, or in pa-
tients with refractory pain who have failed to respond to 
previous endoscopic and surgical treatment [60]. The 
PancreasFest recommendations for TP-IAT include in-
tractable pain for which medical, endoscopic, or prior 
surgery have failed, but do not specify the time to propose 
surgery, only stating that patient and disease characteris-
tics should be considered [61].
It is hard to determine the correct timing of surgery, 
but evidence is mounting that timely surgical interven-
tion can at least delay the progression of pancreatic insuf-
ficiency [52, 57]. In an international survey, 58% of the 
pancreatic specialists regard early surgical intervention 
(as soon as opioid analgesics are required) as superior to 
the step-up approach of medical treatment, followed by 
endoscopic interventions and surgery as a last resort [60]. 
Ahmed Ali et al. [62] state that surgery should be consid-
ered earlier in the course of CP, suggesting that it should 
be proposed within 3 years of symptom evolution. In the 
same sense Yang et al. [63] suggest that surgery within 
26.5 months of diagnosis is associated with improved 
pain control. Several studies show that surgery in the lat-
er stages of CP results in central sensitization [64, 65], 
poor pain relief [63], and increased risk of cancer [66].
Conclusion
CP is a complex disease that should be treated by ex-
perienced teams of gastroenterologists, radiologists, sur-
geons, and nutritionists in a multidisciplinary environ-
ment. Medical treatment includes lifestyle modification, 
nutrition, exocrine and endocrine pancreatic insufficien-
cy correction, and pain management. Up to 60% of pa-
tients will ultimately require some type of endoscopic or 
surgical intervention for treatment. However, regardless 
of the modality, they are often ineffective unless smoking 
and alcohol cessation is also achieved. Surgery retains a 
major role in the treatment of CP patients with intractable 
chronic pain or suspected pancreatic mass. For other 
complications like biliary or gastroduodenal obstruction, 
pseudocyst drainage should be performed endoscopi-
cally.
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